Ovid Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Ovid Therapeutics' es Jeremy Levin , nombrado en Mar 2015, tiene una permanencia de 9.08 años. compensación anual total es $3.13M, compuesta por 19.4% salario y 80.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.17% de las acciones de la empresa, por valor de $11.52M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 4.1 años, respectivamente.
Información clave
Jeremy Levin
Chief Executive Officer (CEO)
US$2.1m
Compensación total
| Porcentaje del salario del CEO | 29.3% |
| Permanencia del CEO | 9.2yrs |
| Participación del CEO | 5.2% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 4.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024
Apr 09We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth
Nov 10
Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth
Jun 27Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation
Mar 13Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Sep 09Ovid Therapeutics GAAP EPS of -$0.21 beats by $0.04
Aug 09We Think Ovid Therapeutics (NASDAQ:OVID) Needs To Drive Business Growth Carefully
Jun 09Ovid Therapeutics: Good Entry Point For Investors
Jun 18Ovid Therapeutics appoints Jeff Rona as CFO
Jun 04Ovid Therapeutics Inc. (NASDAQ:OVID) Could Be Less Than A Year Away From Profitability
Apr 16Analysts Just Made A Captivating Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) Forecasts
Mar 20Ovid Therapeutics Inc. (NASDAQ:OVID) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates
Mar 18We're Keeping An Eye On Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
Mar 01Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Shareholder Ownership Skewed Towards Insiders?
Jan 25Revisiting Ovid Therapeutics
Jan 14Would Shareholders Who Purchased Ovid Therapeutics' (NASDAQ:OVID) Stock Three Years Be Happy With The Share price Today?
Dec 21Ovid Therapeutics misses goal in Angelman syndrome treatment
Dec 01Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$625k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$49m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$3m | US$607k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$68m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$847k | US$584k | US$120m |
| Sep 30 2021 | n/a | n/a | US$123m |
| Jun 30 2021 | n/a | n/a | US$117m |
| Mar 31 2021 | n/a | n/a | US$110m |
| Dec 31 2020 | US$2m | US$560k | -US$81m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$76m |
| Mar 31 2020 | n/a | n/a | -US$67m |
| Dec 31 2019 | US$3m | US$530k | -US$60m |
| Sep 30 2019 | n/a | n/a | -US$56m |
| Jun 30 2019 | n/a | n/a | -US$53m |
| Mar 31 2019 | n/a | n/a | -US$53m |
| Dec 31 2018 | US$3m | US$530k | -US$52m |
| Sep 30 2018 | n/a | n/a | -US$50m |
| Jun 30 2018 | n/a | n/a | -US$46m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | US$2m | US$515k | -US$65m |
Compensación vs. Mercado: Jeremy's total compensation ($USD2.14M) is above average for companies of similar size in the US market ($USD1.63M).
Compensación vs. Ingresos: La compensación de Jeremy ha sido consistente con los resultados de la empresa en el último año.
CEO
Jeremy Levin (70 yo)
9.2yrs
Permanencia
US$2,136,546
Compensación
Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, serves as Director of Graviton BioScience Corporation from May 2023. He has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 an...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 9.2yrs | US$2.14m | 5.16% $ 11.2m | |
| Chief Business and Financial Officer | 2.9yrs | US$1.08m | 0.019% $ 42.2k | |
| General Counsel | 5.2yrs | US$1.07m | 0.018% $ 39.7k | |
| Chief Operating Officer | 2.9yrs | US$1.23m | 0.0039% $ 8.5k | |
| Chief Human Resources Officer | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Global Manufacturing & CMC QA | 8.2yrs | US$1.18m | sin datos | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 2.8yrs | sin datos | sin datos | |
| Chief Strategy Officer | 1.8yrs | sin datos | sin datos | |
| Chief Medical Officer | 1.3yrs | sin datos | sin datos | |
| Head of Epilepsy Research | 1.3yrs | sin datos | sin datos | |
| Chief Scientific Officer | less than a year | sin datos | sin datos |
2.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de OVID se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 10.1yrs | US$2.14m | 5.16% $ 11.2m | |
| Chairman of the Scientific & Clinical Advisory Board | 3.1yrs | sin datos | sin datos | |
| Independent Director | 6.9yrs | US$86.66k | 0% $ 0 | |
| Lead Independent Director | 8.5yrs | US$104.16k | 0% $ 0 | |
| Independent Director | 2.8yrs | US$79.16k | 0% $ 0 | |
| Member of Scientific & Clinical Advisory Board | 7.3yrs | sin datos | sin datos | |
| Member of the Scientific & Clinical Advisory Board | 3yrs | sin datos | sin datos | |
| Independent Director | 8.7yrs | US$91.66k | 0.028% $ 61.4k | |
| Independent Director | 2.6yrs | US$71.66k | 0% $ 0 | |
| Member of Scientific & Clinical Advisory Board | 2.8yrs | US$1.59m | sin datos | |
| Member of Scientific & Clinical Advisory Board | 4.2yrs | sin datos | sin datos |
4.2yrs
Permanencia media
67.5yo
Promedio de edad
Junta con experiencia: La junta directiva de OVID se considera experimentada (4.1 años de antigüedad promedio).